Digital twin predictions of patient outcomes enable more efficient and powerful clinical trials

"This variance reduction (with digital twins) could have had a significant impact on the number of subjects we needed…and still preserved the same power…we would have had a faster enrollment, encourage(d) greater patient participation. And ultimately, that would have been cost saving and time saving." Ole Graff, AbbVie's Head of Neurodegeneration, Neuroscience Clinical Development. Unlearn x AbbVie, AD/PD 2025 Conference, Vienna, Austria.